Dexcom Inc. Stock
Dexcom Inc. Stock
A loss of -1.750% shows a downward development for Dexcom Inc..
Dexcom Inc. is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
With a target price of 136 € there is a slightly positive potential of 15.33% for Dexcom Inc. compared to the current price of 117.92 €.
Our community identified positive and negative aspects for Dexcom Inc. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Dexcom Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Dexcom Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dexcom Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Dexcom Inc. | -1.750% | -1.140% | -9.695% | 5.663% | 5.323% | 67.025% | 352.842% |
Dentsply Sirona Inc. | -0.460% | -1.446% | -14.153% | -30.712% | -19.515% | -54.514% | -46.548% |
Teleflex Inc. | -2.130% | -1.058% | -10.096% | -18.696% | -17.257% | -44.345% | - |
Baxter International | -0.290% | -3.355% | -15.247% | -17.071% | -5.478% | -53.495% | -52.006% |
Comments
DexCom, Inc. (NASDAQ: DXCM) had its price target raised by analysts at Raymond James from $151.00 to $160.00. They now have a "strong-buy" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom, Inc. (NASDAQ: DXCM) had its price target raised by analysts at UBS Group AG from $153.00 to $163.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom, Inc. (NASDAQ: DXCM) had its price target raised by analysts at Citigroup Inc. from $148.00 to $161.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
News
DexCom (DXCM) Q1 2024 Earnings Call Transcript
Dexcom Reports First Quarter 2024 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.
First Quarter 2024 Financial Highlights:
-
Revenue grew 24% year-over-year to
2 Growth Stocks to Buy Hand Over Fist in April
Earnings season, which is fast approaching, is often somewhat volatile for the stock market. Companies that overdeliver or fail to deliver can see their share prices move significantly overnight.